BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28655808)

  • 1. Chronic myeloid leukemia: room for improvement?
    Baccarani M; Pane F; Rosti G; Russo D; Saglio G
    Haematologica; 2017 Jul; 102(7):1131-1133. PubMed ID: 28655808
    [No Abstract]   [Full Text] [Related]  

  • 2. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
    Mahon FX
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 4. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 6. Pioglitazone with imatinib in CML may reduce residual disease.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e70. PubMed ID: 28089103
    [No Abstract]   [Full Text] [Related]  

  • 7. The Role of Early Molecular Response in the Management of Chronic Phase CML.
    Harrington P; Kizilors A; de Lavallade H
    Curr Hematol Malig Rep; 2017 Apr; 12(2):79-84. PubMed ID: 28405921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching drugs midstream for patients with chronic myeloid leukemia.
    DeAngelo DJ
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):466-8. PubMed ID: 25322328
    [No Abstract]   [Full Text] [Related]  

  • 9. Asciminib as a new option in the treatment of chronic myeloid leukemia.
    İbiş B; Tiribelli M; Eşkazan AE
    Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating unconventional T-cell subsets during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia.
    Konuma T; Kohara C; Watanabe E; Mizukami M; Nagai E; Kato S; Takahashi S; Tojo A
    Eur J Haematol; 2019 Dec; 103(6):623-625. PubMed ID: 31512295
    [No Abstract]   [Full Text] [Related]  

  • 11. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
    Hehlmann R; Müller MC; Lauseker M; Hanfstein B; Fabarius A; Schreiber A; Proetel U; Pletsch N; Pfirrmann M; Haferlach C; Schnittger S; Einsele H; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Ehninger G; Heim D; Heimpel H; Nerl C; Krause SW; Hossfeld DK; Kolb HJ; Hasford J; Saußele S; Hochhaus A
    J Clin Oncol; 2014 Feb; 32(5):415-23. PubMed ID: 24297946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of first-line chronic myelogenous leukemia treatment.
    Fava C; Rege-Cambrin G; Saglio G
    Ann Hematol; 2015 Apr; 94 Suppl 2(Suppl 2):S123-31. PubMed ID: 25814078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia: reaching for the cure.
    Nencioni A; Cea M; Montecucco F; Gobbi M; Patrone F
    Curr Cancer Drug Targets; 2013 Sep; 13(7):709-10. PubMed ID: 23957630
    [No Abstract]   [Full Text] [Related]  

  • 15. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
    Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
    [No Abstract]   [Full Text] [Related]  

  • 16. Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.
    Carella AM; Beltrami G; Pica G; Carella A; Catania G
    Leuk Lymphoma; 2012 Jul; 53(7):1409-11. PubMed ID: 22233113
    [No Abstract]   [Full Text] [Related]  

  • 17. An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission.
    Kunbaz A; Eskazan AE
    Expert Rev Hematol; 2019 Jul; 12(7):477-480. PubMed ID: 31166812
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
    Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
    J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
    Hochhaus A; Ernst T; Eigendorff E; La Rosée P
    Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.